<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01748448</url>
  </required_header>
  <id_info>
    <org_study_id>2012LRDVDCM</org_study_id>
    <secondary_id>2012-002125-30</secondary_id>
    <nct_id>NCT01748448</nct_id>
  </id_info>
  <brief_title>Vitamin D Supplementation in Cutaneous Malignant Melanoma Outcome</brief_title>
  <acronym>ViDMe</acronym>
  <official_title>Vitamin D Supplementation in Cutaneous Malignant Melanoma Outcome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitaire Ziekenhuizen Leuven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Katholieke Universiteit Leuven</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Universitaire Ziekenhuizen Leuven</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess whether vitamin D supplementation after surgery of a first cutaneous malignant
      melanoma protects against relapse of the disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To assess whether vitamin D supplementation, in the follow up period after diagnosis and
      surgery of a first cutaneous malignant melanoma, has a protective effect on relapse of
      cutaneous malignant melanoma and whether this protective effect correlates with vitamin D
      levels in serum and vitamin D receptor (VDR) immunoreactivity in the primary tumor.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">September 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Relapse free survival</measure>
    <time_frame>study duration maximum 3,5 years</time_frame>
    <description>Disease free survival will be the primary endpoint of this phase III trial. Patients are enrolled during a recruitment phase of three years maximum. Study duration for one patient is maximum 3,5 years or until relapse occurs.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Melanoma subtype, as assessed clinically and histologically</measure>
    <time_frame>study duration maximum 3,5 years</time_frame>
    <description>Vitamin D levels at diagnosis will be correlated with melanoma subtype, as assessed clinically and histologically.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Melanoma site, as clinically recorded</measure>
    <time_frame>study duration maximum 3,5 years</time_frame>
    <description>Vitamin D levels at diagnosis will be correlated with melanoma site, as clinically recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>25(OH)D3 serum levels</measure>
    <time_frame>study duration maximum 3,5 years</time_frame>
    <description>25(OH)D3 serum levels will be recorded at diagnosis and at 6 months intervals up to final study visit. Genetic variability of Vitamin D pathway will be correlated with 25(OH)D3 serum levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stage of melanoma patient</measure>
    <time_frame>study duration maximum 3,5 years</time_frame>
    <description>Vitamin D levels at diagnosis and genetic variability of the vitamin D pathway will be correlated with stage of melanoma patient at diagnosis according to the 2009 American Joint Committee of Cancer (AJCC) Melanoma staging and classification</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Safety endpoints:Incidence and severity of adverse events</measure>
    <time_frame>study duration maximum 3,5 years</time_frame>
    <description>Incidence and severity of adverse events will be recorded every 3 months up to final study visit.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Cutaneous Malignant Melanoma</condition>
  <arm_group>
    <arm_group_label>Vitamin D</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Every month 100 000 units of Vitamin D in syringe oral dispenser is taken . Study duration is maximum 3,5 years or until relapse occurs</description>
  </arm_group>
  <arm_group>
    <arm_group_label>arachides oleum raffinatum</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Every month 100 000 units of vitamin D in syringe Oral dispenser is taken. Study duration is maximum of 3.5 years or until relapse occurs</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin D</intervention_name>
    <description>prospective interventional randomized double blind placebo controlled trail
clinical setting (tertiary university hospital)
investigator driven, no pharmaceutical sponsor
cutaneous malignant melanoma patients
add- on study (placebo or vitamin D) on top of optimal standard care
1:1 inclusion ratio (placebo:Vitamin D)
randomisation after informed consent and screening</description>
    <arm_group_label>Vitamin D</arm_group_label>
    <other_name>D-Cure</other_name>
    <other_name>Cholecalciferol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>arachides oleum raffinatum</intervention_name>
    <arm_group_label>arachides oleum raffinatum</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Older than 18 years and younger than 80 years of age.

          2. Histologically proven malignant melanoma, stage one B (IB) to three (III) Not
             participating in other clinical trial.

          3. The only treatment for melanoma is surgical treatment.

          4. Complete resection of melanoma.

          5. Single primary invasive cutaneous melanoma

          6. Signed ethical committee approved informed consent

          7. Serum phosphate, serum calcium at the entry of the study within normal limits of
             laboratory reference

        Exclusion criteria

          1. Pregnant/lactating women or planning on becoming pregnant during the study

          2. Known hypersensitivity to vitamin D or its components.

          3. Pre-existing renal stone disease, chronic renal disease with glomerular filtration
             rate (eGFR) &lt; 30 mL/min/1.73 m2 or renal dialysis.

          4. Liver failure or chronic liver disease with liver enzymes &gt; 2 fold upper limit of
             normal (ULN).

          5. History of parathyroid disease or granulomatous disease (TBC and sarcoidosis)

          6. History of malabsorption syndrome or any medical condition that might interfere with
             vitamin D absorption.

          7. History of small intestine resection.

          8. History of other malignancy within the last 5 years except for carcinoma in situ of
             the cervix or basal cell carcinoma or squamous cell carcinoma of the skin or in situ
             malignant melanoma.

          9. Chronic alcohol abuse.

         10. Medical or logistic problems likely to preclude completion of the study.

         11. Taking medication that predisposes to hypercalcemia (digoxin, lithium, thiazide
             diuretics) or taking medication that would affect metabolism of vitamin D
             (anticonvulsants, corticosteroids, H2-receptor antagonists)

         12. Intake of vitamin D supplements within 6 months prior to entry of the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marjan Garmyn, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitaire Ziekenhuizen Leuven</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marjan Garmyn, MD, PhD</last_name>
    <phone>+32 16337950</phone>
    <phone_ext>37950</phone_ext>
    <email>marjan.garmyn@uzleuven.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Julie Desmedt, MD</last_name>
    <phone>+32 16337864</phone>
    <phone_ext>37864</phone_ext>
    <email>Julie.Desmedt@uzleuven.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Antwerpen, Dermatology</name>
      <address>
        <city>Edegem</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>UZ Sint Rafael ( UZLeuven)</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marjan Garmyn, MD PhD</last_name>
      <phone>+3216337950</phone>
      <phone_ext>37950</phone_ext>
      <email>marjan.garmyn@uzleuven.be</email>
    </contact>
    <contact_backup>
      <last_name>Julie De Smedt, MD</last_name>
      <phone>+3216337864</phone>
      <phone_ext>37864</phone_ext>
      <email>Julie.Desmedt@uzleuven.be</email>
    </contact_backup>
    <investigator>
      <last_name>Marjan Garmyn, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chef de Service du Service Universitaire de Dermatologie</name>
      <address>
        <city>Li√®ge</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dep. of Dermatology, Medical and Health Science Center University of Debrecen</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Hungary</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 5, 2012</study_first_submitted>
  <study_first_submitted_qc>December 11, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 12, 2012</study_first_posted>
  <last_update_submitted>October 24, 2017</last_update_submitted>
  <last_update_submitted_qc>October 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cutaneous malignant melanoma</keyword>
  <keyword>Vitamin D</keyword>
  <keyword>Cholecalciferol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

